Of the 28 selected kinases in our focused studies, PLK1 is the leading candidate, based on its activity in inhibiting cancer cell growth, and in particular, its activity against the TICs once silenced by siRNA or by the small-molecule inhibitor, BI 2536. This evidence concerns the gene PLK1 and cancer.